BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1233 related articles for article (PubMed ID: 28564525)

  • 1. Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens.
    Abuhelaiqa E; Friedlander R; Aull M; Putheti P; Sharma V; Suthanthiran M; Dadhania D
    Clin Transpl; 2016; 32():83-91. PubMed ID: 28564525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Relevance of Donor-Specific IgM Antibodies in HLA Incompatible Renal Transplantation: A Retrospective Single-Center Study.
    Babu A; Andreou A; Briggs D; Krishnan N; Higgins R; Mitchell D; Barber T; Daga S
    Clin Transpl; 2016; 32():173-179. PubMed ID: 28564535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-Specific HLA Antibodies: A Review of Data Published in 2016.
    Idica A; Everly MJ
    Clin Transpl; 2016; 32():13-22. PubMed ID: 28564519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.
    Michielsen LA; Wisse BW; Kamburova EG; Verhaar MC; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; van Zuilen AD
    Nephrol Dial Transplant; 2019 Jun; 34(6):1056-1063. PubMed ID: 30365008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation.
    Morath C; Döhler B; Kälble F; Pego da Silva L; Echterdiek F; Schwenger V; Živčić-Ćosić S; Katalinić N; Kuypers D; Benöhr P; Haubitz M; Ziemann M; Nitschke M; Emmerich F; Pisarski P; Karakizlis H; Weimer R; Ruhenstroth A; Scherer S; Tran TH; Mehrabi A; Zeier M; Süsal C
    Front Immunol; 2020; 11():1886. PubMed ID: 32983110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.
    Marfo K; Ajaimy M; Colovai A; Kayler L; Greenstein S; Lubetzky M; Gupta A; Kamal L; de Boccardo G; Masiakos P; Kinkhabwala M; Akalin E
    Transplantation; 2014 Nov; 98(10):1082-8. PubMed ID: 24873780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY; Kaneku H; Farmer DG
    Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies.
    Arnold ML; Ntokou IS; Doxiadis II; Spriewald BM; Boletis JN; Iniotaki AG
    Transpl Int; 2014 Mar; 27(3):253-61. PubMed ID: 24118579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.
    DeVos JM; Gaber AO; Knight RJ; Land GA; Suki WN; Gaber LW; Patel SJ
    Kidney Int; 2012 Sep; 82(5):598-604. PubMed ID: 22622504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
    Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
    Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.